TOP NEWS: J&J to restart rollout of Covid-19 jab on EMA guidance
Tue, 20th Apr 2021 17:36
(Alliance News) - Johnson & Johnson on Tuesday announced that it will resume the rollout of its Covid-19 vaccine in Europe following the European Medicines Agency's updated guidance for the jab.
The EU's drug watchdog announced earlier Tuesday that blood clots should be listed as a "very rare" side effect of the J&J coronavirus vaccine but its benefits still outweigh the risks.
The guidance follows a review of a small number of cases of a rare adverse event involving blood clots in combination with low platelet counts that can occur within approximately one to three weeks following injection with the company's Covid-19 vaccine.